2022版ELN指南的更新,对于AML患者的精准预后分层也将具有重要的指导意义。 参考文献 [1] Hartmut Döhner, Elihu Estey, et al.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017 ...
为评估ELN-2022风险分层系统相较于ELN-2017的预后价值,安徽医科大学第一附属医院葛健教授团队开展了一项真实世界的队列研究,分析了363例原发AML患者的临床特征和预后结局,阐释了ELN-2022的预后价值。 01 研究方法 该研究纳入了2017年1月-2...
Comprehensive analyses of the molecular heterogeneity of acute myelogenous leukemia, AML, particularly when malignant cells retain normal karyotype, has significantly evolved. In 2022, significant revisions were introduced in the World Health Organization (WHO) classification and the European Leukemia...
A Focus on Intermediate-Risk Acute Myeloid Leukemia: Sub-Classification Updates and Therapeutic Challenges 2022, Cancers Issue Highlights—July 2022 2022, Cytometry Part B - Clinical CytometryDetails regarding the original AML1310 trial collection data methods can be obtained by contacting adriano.venditti...
This study reports the following: (1) frequency of TP53 comutation within each component of the European LeukemiaNet 2022 acute myeloid leukemia risk classification, (2) relevance of TP53 mutated variant allelic fraction <10%, (3) prognostic impact of -7,-5/del(5q),-17/abn(17p), complex...
Outcome Prediction By the New 2022 European Leukemia Net (ELN) Genetic-Risk Classification for Adult Patients (Pts) with Acute Myeloid Leukemia (AML): An Alliance Studydoi:10.1182/blood-2022-167352Krzysztof Mrózek MDPhDJessica Kohlschmidt PhD...
Beat-AML 2024 ELN–refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapydoi:10.1182/bloodadvances.2024013685Although the 2022 European LeukemiaNet (ELN) acute myeloid leukemia (AML) risk classification reliably predicts outcomes in younger patients treated with...
Prognostic significance of myelodysplasia-related changes according to the WHO classifica‑ tion among ELN-intermediate-risk AML patients. Am J Hematol. 2015;90:E22-4.
ELN分层体系主要在接受强化诱导治疗IC的患者(n=345)中得到验证:根据ELN 2022标准,与中危组相比,低危AML患者的生存期显著延长(HR 0.38;95%CI,0.24-0.59;P<0.001),而不良风险组患者的生存期显著较差(HR 1.58;95%CI,1.12-2.25;P=0.01);...
表:综合ELN22分组和移植前缓解状态不同AML患者的移植预后 鉴于移植前缓解状态对移植的结局有显著的影响,因此我们将ELN2022风险分层与移植前缓解状态进行整合,进而开发出一个新的风险分层系统【Refined(RS) ELN2022】以更加准确的预测AML患者...